



## Marie Liesse Le Corfec, Head of Global Portfolio Marketing at BD Pharmaceuti- cal Systems

***“BD is offering support to COVID-19 drug and vaccine developers.”***

**A**s one of the largest global medical technology companies in the world, our role in advancing the world of health has never been clearer than it is today. BD is deploying our broad capabilities, expertise and scale to address critical health needs related to coronavirus including our diagnostic offerings to identify current or past exposure to SARS-CoV-2, real-time informatics and electronic surveillance technology, and essential medical devices to support patient care.

This can also include anticipating the future mass administration of Covid-19 vaccines. As most of those vaccines may be initially launched in vials, syringes will be needed for immunization campaigns. BD devices have been used

in some of the world’s most critical vaccination campaigns, such as the Salk Polio vaccine trials, the Measles Initiative in partnership with American Red Cross and the annual flu campaign across the globe.

In parallel, convenient prefilled formats will be developed by the industry and BD, reference supplier of prefillable injection devices for vaccines, is also preparing to support this effort. More generally, BD is offering support to Covid-19 drug and vaccine developers to help accelerate time-to-market and support global health through a variety of means.

BD instruments, reagents and software solutions help researchers study immune

responses to viral infections, isolate and characterize virus-specific T and B cells, assess immunogenicity of vaccine candidates, perform multiomic analysis of immune cells of interest and simplify complex data analysis and visualization.

BD also announced new products to help aid in the detection and identification of Covid-19 past or present infection, including multiple molecular tests for the detection of the virus and serology tests for detection of antibodies. We are collaborating with peers from across the industry, U.S. Department of Health and Human Services, U.S. Food and Drug Administration and private partners to identify and validate additional swab types as well as transport medium options in order to expand capacity and alternative collection methods.

BD's broad portfolio of medication delivery devices such as safety-engineered and auto-disable injection devices can assist rapid deployment of novel Covid-19 treatments and vaccines trials.

BD pre-fillable syringes are typically used by the generic drug industry to supply ready to administer acute drugs in hospitals, saving on critical nursing time. Our pre-fillable devices are also used by the industry to enable safe and convenient administration of parenteral or nasal vaccines. We are now closely working with the industry,

***“ We are now closely working with the industry, NGOs and governments to identify and anticipate supply for large immunization campaigns.”***

NGOs and governments to identify and anticipate supply for large immunization campaigns. BD's expertise in combination product development can also support vaccine developers in predicting drug container compatibility before scale-up and support their dossier development for regulatory filing.

In addition to direct support to the health care industry, BD is deploying \$1.1 million in cash and product donations to seven non-profit organizations – Direct Relief, the International Medical Corps, Americares, the World Health Organization-United Nations Foundation Covid-19 Solidarity Response Fund, Project HOPE, the CDC Foundation and the Wuhan Red Cross – to advance their work to contain Covid-19, support healthcare workers and treat patients in countries throughout the world.